Detalhe da pesquisa
1.
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Ann Hematol
; 101(1): 131-137, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625831
2.
Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.
J Med Econ
; 26(1): 843-849, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294103
3.
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.
Leuk Res
; 115: 106809, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220060
4.
Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population.
Int J Chron Obstruct Pulmon Dis
; 17: 593-608, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35342290
5.
Incremental Costs Associated with Length of Hospitalization Due to Viral Pneumonia: Impact of Intensive Care and Economic Implications of Reducing the Length of Stay in the Era of COVID-19.
Clinicoecon Outcomes Res
; 12: 723-731, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33293840